# Enveda raises $311 million to advance AI-assisted drug candidates

_Published Friday, September 25, 2026 at 9:21 AM EDT · Capital, AI · Latest · Tier 2 — Notable_

![Upscale AI Seeks New Funding At $2 Billion Valuation Despite No Product Release — Primary](https://digitalmarketreports.com/wp-content/uploads/2026/04/image-140.png)

Enveda has raised $311 million in Series E financing at a $2 billion valuation as it moves drug candidates found through its AI-assisted search of natural compounds into human testing. Catalio Capital Management led the round, with Iconiq among the participants. Enveda plans to fund later-stage work on existing clinical candidates and bring more treatments for inflammatory and metabolic conditions into trials.

Its ENV-308 candidate is designed to help people maintain weight after stopping GLP-1 treatments. Enveda reported positive Phase 1 results for that candidate in August; further studies are planned.

## Sources

- [DMR News](https://digitalmarketreports.com/news/92559/enveda-raises-311-million-at-2-billion-valuation-to-advance-ai-discovered-drugs/)

---
Canonical: https://techandbusiness.org/newswire/b_caiwal43h70vmS9GDpBu
Published: 2026-09-25T13:21:32.602Z
Story chronology: 2026-09-25T10:00:00.000Z
Retrieved: 2026-09-25T14:57:20.497Z
Publisher: Tech & Business (techandbusiness.org)